

# W30: Post prostatectomy urinary incontinence: Questions

the patients ask

Workshop Chair: Carlos D'Ancona, Brazil 31 August 2018 09:00 - 10:30

Start	End	Торіс	Speakers
09:00	09:05	introduction	Carlos D'Ancona
09:05	09:15	Much is said about physical therapy, but what is the evidence?	Giulio Del Popolo
09:15	09:25	New techniques to evaluate the degree of incontinence	Andrew Gammie
09:25	09:35	How to select the technique	Carlos D'Ancona
09:35	09:45	For How long is the surgery is?	Sender Herschorn
09:45	09:55	What to do if the patient improves but is still unsatisfied	Giulio Del Popolo
09:55	10:05	How do you deal with complications: infection, erosion	Sender Herschorn
10:05	10:30	Discussion	Carlos D'Ancona
			Sender Herschorn
			Andrew Gammie
			Giulio Del Popolo

# Aims of Workshop

The objective of this workshop is to identify and answer the main questions of patients with urinary incontinence after radical prostatectomy and to allow the discussion of how to interpret and solve their problems. The discussion of the selected questions attempts to observe the anxieties and concerns of the patients affected by this comorbidity. The expected outcome is to learn how we can improve treatment under emotional and functional aspects.

# **Learning Objectives**

Classify the grade of urinary incontinence, the results of physiotherapy and expectation of each type of surgery.

# Learning Outcomes

Identify patient anxieties and select the more appropriate treatment.

# **Target Audience**

Urologists, Nurses, Physiotherapists.

# Advanced/Basic

Basic

# **Conditions for Learning**

This is an interactive workshop.

# Suggested Learning before Workshop Attendance

Trofimenko V, Myers JB, Brant WO. Post-Prostatectomy Incontinence: How Common and Bothersome Is It Really? Sex Med Rev. 2017 Oct;5(4):536-543. doi: 10.1016/j.sxmr.2017.05.001. Epub 2017 Jun 20.

Gomes CS, Pedriali FR, Urbano MR, Moreira EH, Averbeck MA, Almeida SHM. The effects of Pilates method on pelvic floor muscle strength in patients with post-prostatectomyurinary incontinence: A randomized clinical trial. Neurourol Urodyn. 2017 May 2. doi: 10.1002/nau.23300. [Epub ahead of print]

Kretschmer A, Nitti V. Surgical Treatment of Male Postprostatectomy Incontinence: Current Concepts. Eur Urol Focus. 2017 Nov 22. pii: S2405-4569(17)30263-8. doi: 10.1016/j.euf.2017.11.007. [Epub ahead of print]

# **Suggested Reading**

Biardeau X, Aharony S; AUS Consensus Group, Campeau L, Corcos J. Artificial Urinary Sphincter: Report of the 2015 Consensus Conference. Neurourol Urodyn. 2016 Apr;35 Suppl 2:S8-24.

Comiter CV, Rhee EY, Tu LM, Herschorn S, Nitti VW. The virtue sling--a new quadratic sling for postprostatectomy incontinence--results of a multinational clinical trial. Urology. 2014 Aug;84(2):433-8.

Crivellaro S, Singla A, Aggarwal N, Frea B, Kocjancic E. Adjustable continence therapy (ProACT) and bone anchored male sling: Comparison of two new treatments of post prostatectomy incontinence. Int J Urol. 2008 Oct;15(10):910-4.

Costa Cruz DS, D'Ancona CA, Baracat J, Alves MA1, Cartapatti M, Damião R. Parameters of two-dimensional perineal ultrasonography for evaluation of urinary incontinence after Radical Prostatectomy. Int Braz J Urol. 2014 Sep-Oct;40(5):596-604.

Romano SV, Metrebian SE, Vaz F, Muller V, D'Ancona CA, de Souza EA, Nakamura F. [Long-term results of a phase III multicentre trial of the adjustable male sling for treating urinary incontinence after prostatectomy: minimum 3 years]. Actas Urol Esp. 2009 Mar;33(3):309-14.

# Much is said about physical therapy, but what is the evidence? Del Popolo Giulio

# Neuro-Urology Unit; Careggi University Hospital Firenze (Italy)

Men who develop PPI (post-prostatectomy incontinence) should be treated through conservative methods in the first year, as continence status will continue to evolve. The value of the approaches to conservative management of post-prostatectomy incontinence after radical prostatectomy remains uncertain despite improvement of surgical open and video laparoscopic or robotic technique in preserving neurovascular bundle. The evidence is conflicting about physical therapy interventions after prostatectomy, which may include pelvic floor exercises (PFE), electrical stimulation (ES), biofeedback training (BFB) and also behavioural therapy (BT). Although, in general, there is enough evidence to demonstrate the beneficial effects of pelvic floor muscles training (PFMT) (Anderson et al., 2015), there is insufficient evidence to demonstrate the right time to begin PF training after surgery nor the amount and type of exercises to be performed, i.e., there is not a clear protocol to be followed. Conclusions are difficult to make because of the heterogeneity of the results, and most studies do not describe exactly treatments. We currently do not know in most cases pelvic floor muscle strength and innervation prior to surgery, even if has been demonstrated that anatomic support and pelvic innervation are essential factors in the aetiology of PPI and that their damage leads to higher rates of PPI (Heesakker et al., 2017).

In particular the role of PFE has been debated: data show that strength of pelvic floor muscles (PFM) and striated urethral sphincter (SUS) plays a crucial role in maintenance of urinary continence and if the urethra is short this may accompany lesser volume of SUS muscle fibers available to compress the urethra (Stafford 2018).

Despite the variety of outcome measurements used to assess PPI, several trials showed that PFMT was significantly more effective than no treatment or sham treatment in the immediate postoperative period and that preoperative and postoperative PFMT is better than only postoperative PFMT (Van Kampen et al., 2000; Manassero et al., 2007). The results of preoperative PFMT on incontinence were positive in several trials, and postoperative PFMT is better than only information about PFMT before and after surgery (Burgio et al., 2006; Centemero et al., 2010; Tienforti et al., 2012).

Biofeedback involves the use of a device to provide visual or auditory feedback: no additional effect of biofeedback was found in men undergoing a radical prostatectomy; the positive role of Functional Electrical Stimulation (FES) was confirmed (Yokoyama et al., 2004; Liu et al., 2008; Yamanishi et al., 2010) using a rectal probe or transcutaneous electrodes to facilitate awareness of contraction of the pelvic floor muscles or to inhibit detrusor contraction.

Future studies should focus on identification of men more likely to benefit from conservative interventions, as symptoms of incontinence after prostatectomy tend to improve over time without intervention. Screening those with potential intrinsic sphincter deficiency post-surgery.

The specific effectiveness of a physical therapeutic approach for incontinence after prostatectomy can only be evaluated with randomised controlled studies.

# <u>New Techniques to Evaluate the Degree of Incontinence</u> Andrew Gammie, Bristol Urological Institute, UK

Leakage of any amount, however small, is bothersome to the patient. The clinician may be interested to ask how much leakage, what is the cause etc., but the patient is more likely to be concerned about stopping it completely, and what intervention might be possible to achieve that.

It has recently been stated that 'the role of urodynamic testing to assess these patients and offer treatment is still to be determined'1. It is clear, though, that the combined function of the sphincter and the pelvic floor is vital in this group of patients. There may then be a role for urethral pressure profilometry (UPP) in this area, dealing as it does with the changes in pressure through the functional length of the urethra.

Data from a small number of patients in our centre shows that the UPP traces can demonstrate the action of the pelvic floor on the continence mechanism, alongside a measurement of sphincter closure pressure. It can also demonstrate the different action of pelvic floor contraction and abdominal straining by measuring pressure changes above and below the sphincter level. Voluntary and spontaneous (evoked) coughs could be used within the protocol, as these are known to have different effects2.

Thus the UPP test may have a use in biofeedback, in assessing the relation between urethral closure pressure and leakage and evaluating the capacity of the pelvic floor to aid continence. The patient can then be advised on the degree of improvement possible through physiotherapy.

1. Arcila-Ruiz M, Brucker BM. The Role of Urodynamics in Post-Prostatectomy Incontinence. Curr Urol Rep. 2018; 19(3):21.

2. Stafford RE, Mazzone S, Ashton-Miller JA, Constantinou C, Hodges PW. Dynamics of male pelvic floor muscle contraction observed with transperineal ultrasound imaging differ between voluntary and evoked coughs. J Appl Physiol 2014; 116:953-960.

# How to select the technique? Calos D'Ancona, UNICAMP, Brazil.

To treat post prostatectomy incontinence, the most used techniques are: artificial sphincter and sling. The sling can be compressive or repositioning and adjustable or not. How to select the best technique for the patient? It depends on the grade of incontinence, the preference of the patient and the ability to action the artificial sphincter. How to select the technique between sling and artificial sphincter?

There are many maneuvers or techniques to grade the incontinence and we want to analyze the effectiveness of each technique: numbers of pads, weight pad test, reposition test, ultrasound and urodynamics. Some authors separate in mild, moderate and severe incontinence, but what is the threshold?

We performed a study to answer this question. And the answer is ......

# References:

Costa Cruz DS, D'Ancona CA, et all, Parameters of two-dimensional perineal ultrasonography for evaluation of urinary incontinence after Radical Prostatectomy. Int Braz J Urol. 2014, 40(5): 596-604.

Fischer MC1, Huckabay C, Nitti VW. The male perineal sling: assessment and prediction of outcome. J Urol. 2007, 177(4): 1414-8.

# <u>What to do if the patient improves but is still unsatisfied</u> Del Popolo Giulio Neuro-Urology Unit; Careggi University Hospital Firenze (Italy)

Patients after surgery ask to maintain or improve their previous urinary continence and sexual function. Despite new surgery technique and early rehabilitation patients can be affected by post-prostatectomy urinary incontinence (PPI) and/or lower urinary symptoms (LUTS) and/or Erectile Dysfunction (ED). If pelvic floor rehabilitation is not enough to obtain patient's satisfaction, medical therapy can improve LUTS and/or continence. Erectile function can be improved by early pharmacological therapy.


Antimuscarinics and B3 agonist can improve bladder control if urgency/frequency and/or urge incontinence is detected. Some study showed also a role of Duloxetine in post-prostatectomy stress urinary incontinence due to sphincter deficiency, but few study has been published and also if Duloxetine showed a good efficacy but only in the short time follow up. If oral treatment fails urodynamic evaluation is needed and a second level treatment may be taken in consideration such as percutaneous tibial nerve stimulation (PTNS), sacral neuromodulation or botulinum toxin intradetrusor injection. If botulinum toxin is used the patient must informed regarding the risk of post treatment urinary retention and need of a period of intermittent catheterization. In case of light or mild stress urinary incontinence persistence the sling procedure for light or mild urinary incontinence, are indicated.

In patients with overactive bladder associated with stress urinary continence recovery of continence is hard to reach, especially if bladder show a very low capacity or reduced bladder compliance.


In patients affected by incontinence with associated voiding dysfunction and high residual urine, first of all is mandatory to ensure at least a complete bladder voiding. Intermittent catheterization should be taken in consideration as first approach. Regarding erectile dysfunction there are some data showing that early use of PDE5 inhibitors can improve recovery erectile potency. But if despite oral therapy the patient is not satisfied intracavernous prostaglandin injection can be offered starting the treatment with a low dosage. Last option is the surgical implantation of a penile prosthesis. Penile prosthesis and artificial sphincter despite a good efficacy at short and medium follow up, we must inform the patient about risk of complications such as erosion, infection and mechanical malfunctioning.

In conclusion functional outcome after prostatectomy improved in the last ten years. We have conservative, medical and surgical option to recovery continence and sexual activity. Early approach of treatment is recommended to avoid more invasive treatment.





LIFESTYLE





#### LIFESTYLE

#### **Appropriate Body Weight**

AHEAD trial - on a subset of male participants (n=1910).


Prevalent UI at one year were reduced by 38%

support and education group UI decreasing from 11% to 9%

Phelan, Kanaya et al. (2012)

Lifestyle modification interventions promoting weight loss as a tool to reduce urinary incontinence in men who are overweight or obese. (Level of Evidence: 2)


# <section-header><section-header><text><text><text><text><text>




## LIFESTYLE


Lifestyle recommendations such as smoking cessation, healthy eating, appropriate body weight, avoiding excessive caffeine or alcohol are all part of a primary care approach

Few trials have addressed the topic of lifestyle interventions alone for men with UI







































#### iew – Incontinence

Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review


John Heesakkers<sup>a</sup>, Fawzy Farag<sup>h,\*</sup>, Ricarda M. Bauer<sup>c</sup>, Jaspreet Sandhu<sup>d</sup>, Dirk De Ridder<sup>e</sup>, Arnulf Stenzl<sup>7</sup>


#### EUROPEAN UROLOGY 71 (2017) 936-944

Factor	Positive impact	Negative impact	No effect	Study	LE
Age				Nevara (50)	3
				Karakiewicz [51]	3
				Matuashita [52]	3
			-	Kadoreo (53)	3
				Catalona [54]	3
Pre-existing LUTS				Rodrigsanz [60]	3
Functional bladder changes				Lee [48]	3
				Dubbelman [71]	3
				Song [47]	28
TURP before RP				Elder [58]	3
				Palisaar (59)	4
Prostate size				Boczko (64)	3
				Konety [65]	3
				Kadono (53)	3
Membranous urethral length				Newer 1671	26
				Paparel (68)	3
				Matuathita [52]	3
				Borin (69)	2b
				Bakimi (72)	3
Body mass index				Wolin [55]	3
				Wiley [56]	3
				Matuashita [52]	3
				Kadono (53)	3
Salvage RP after RT				Chade [70]	

	Table 2 - Sugical factors contril Filmois Science Detessive disortion Rador activation	Positive Import	Negative	No effect	Staty	
	Scicture Estensive dissection	imped	impact.		wary	LE
	Scicture Estensive dissection					
	Entensive desection				Paparel (53)	3
	Entensive desection				Taygun [28]	
					Sacco [29]	
					Srivastava [73]	3
					Stokenburg [5]	
					Setti [7] Marice [41]	1
	Barro slich				Marice [41] Record 199	4
	Reaction Section				Kacco [19]	24
	Antentor English				Harten [16]	19
	Personal Industry				Stokenburg (17)	24
					Schloren [18]	22
					Solumik (6)	1
	Lasity of the pesterior support				Recent [74]	20
	and the process support				Rahaler [75]	20
					Sakind [27]	1
	Neurosascular bundle damage				Momenti 1451	20
					Ontaria [37]	24
					Ordensir [38]	3
					Kaye [28]	3
					Sacco [29]	3
					Stokenburg [17]	24
					Barkhand (40)	20
	Devacularization				Oudernir [38]	3
					Myers (28)	4
					Yacel [77]	
	LE - level of evidence.					
E 114	-1-1					
	<sup>संजा</sup> tors affecting statectomy	urinary	incontine	ence duri	ng robotic	radical














Andrew Gammie	PHILADELPHIA
Affiliations to disclose <sup>+</sup> :	
Astellas, Ipsen consultancy	
Andromeda, Digitimer, Laborie project grants	
* All Brancial ties (over the last year) that you may have with any business organization with respect to the subjects mentioned du	ing your presentation
	ing your presentation
Funding for speaker to attend.	
Funding for speaker to attend:	
Self-funded	














		PHILADELPHIA
Marina Mari	Fig. 1 has the has a smaller strain of the figure s	
Possibilities for:		
Biofeedback		
<ul> <li>MUCP / leakage relation</li> </ul>		
Pelvic floor capacity		
Prognostic advice		

CS 2018 PHILADELPHIA	C arlos D'Ancona	C PHILAD
How to select the technique? Carlos D'Ancona Professor of Urology UNICAMP	Affiliations to disclose <sup>†</sup> : Ibsen – clinical trial <sup>14</sup> transfer the spectra start and a start to a start on a start on the start to a start on a start on the start to a start on a sta	










ow to evaluate the patient?	PHILADELPHIA	1. Voiding diar	y				o ICS
1. Voiding Diary							
2. Number of pads			0-			ACCIDENTS	
		Ø	23	52	9	\$	্ৰ
3. Pad weight test		Time	Drinks	Urine The real the real of	Accidental leaks	Did you feel a strong urge to go?	What were you doing at the time? Interpret working at
<ol><li>Quality of Life</li></ol>		7-8 (c.m.		000		Van No	
5. Cystoscopy		8-2 (p. m) (b. 10) (p. m)	-	000		746 NO	
5. Cystoscopy		\$5-11 p.m.		0 0 0		Yes No	
<ol><li>Perineal ultrasound</li></ol>		11-12 (cm) montagen 10-14 (cm)	_	000		The No.	
o. Termedi dittasodna		Sitan San	-	000		Yes No	
7. Urodynamics		2-3 mm		000		Yes No	
		Bitam Plam	-	000		Ten No.	
		58am	-		4 0 0	Van No	
		fued	24. J used ny health care las	stigars lodg jurite numbe			



1 hour test		CS 2018 PHILADELP	'HIA
Minimum	<i>→</i>	< 1g	
Mild	$\rightarrow$	> 1 < 10g	
Moderate	$\rightarrow$	> 10 < 50g	
Severe	$\rightarrow$	> 50g	
hither A, BMC Urology, 2007,	7: 2		

1 hour test	PHILADELPHIA
Does not reflect the normal activity of the patient	
Can sub estimate the amount of leakage	
Smither A, BMC Urology, 2007, 7: 2	












	test GICS 2018 PHILADELPHIA	Cystoscopy – reposition test
Good contraction of rabdosphincter Urethral mobility But, how to quantify these variables?		Urethral mobility








Prienal Ultrasound	PHILADELPHIA
We can evaluate the contraction of the pelvic m of the urethra	nuscles and mobilization






Detrusor hypoactivity	PHILADELPHI
Venalize Entri/Oralize Namograma: Protestantor Configuraçãos Se da Esta III (A, A, A	Cumune de presta
	FD = 30 To 18 as
	F7 = N0 PA = 51 F1 = 18 T: 19-04 CKC41 F7 = 67 PA = 52 F7 = 16 T: 19-24 CKC41 F7 = 67 PA = 52 F1 = 10 - 16 T: 19-24 F1 = 10 - 16 T: 19-24 F1 = 10 - 10 - 10 - 10 - 10 - 10 - 10 - 1
	PF = 03 PA = 34 PF = 10 Ti 13:43 Constant) PF = PA = PC =
1 · .	PV=65 PA=56 PD=9 Tx 13x16 Correct do Bacco Takao C Zon Deresión de Plano
• • • • • • • • • • • • • • • • • • •	Tempo até méxime 20 : Phase relatives 6 auto





LPP & Pad weight test
$\begin{array}{c} 800 \\ pad \\ 0 \\ 0 \\ 150 \\ r=0.1748 \\ r=0.4783 \\ r=0.4783 \\ r=0.4783 \\ r=0.3294 \\ r=0.2894 \\ $


Urethral pressure profile (UPP)	PHILADELPHIA
The urethral pressure profile began in 1969, when Brow realized that there was a need to develop a simp method to evaluate the pressure inside the urethra.	
Brown M; Wickham J.E.A : The uretrhal press	ure profile. BJU Int 47:445-8, 1969


Concept of compression zone	O PHILADELPHIA
The region of greater pressure in normal urethra receives compression zone	the term of
It corresponds to the external sphincter	
Griffiths D.J: Urodynamcis. The mechanisms and Hydrodynamics of the Lower Ur	rinary Tract (ed Second). Unite Kindon, ICS, 201






















lation betwe	elation between surgical results of Pura.cont.max and reposition test					
Pacients	Pad weight	Pad weight	Pura.cont.max	Reposition		
	test 24h (g)	test 24h (g)	(cmH2O)	test		
	before	after				
16	750	400	120	Positive		
17	200	0	181	Negative		
18	80	0	186	Positive		
19	1200	600	120	Negative		
20	740	100	154	Positive		
21	1200	570	36	Negative		
22	80	0	184	Positive		
23	1400	670	42	Negative		
24	550	320	101	Positive		
25	245	0	201	positive		



# PHILADELPHIA

Predictive Positive Value (PPV) for cure and improvement in accordance of Pura.cont.max


P <sub>uro.cont.max</sub>	Number of pacients	PPV (%) improvement	PPV (%) cure
180	4	100	100
150	5	100	80
120	7	86	57
100	8	75	50
oser D, D'Ancona C. Int Braz J Uro	l, accept for publication		





Why perform all these test?	OF ICS 2018 PHILADELPHIA
To identify the best technique to fit for the patient	

Sling obtain more indication	PHILADELPHIA
Less complex <ul> <li>Age men, degenerative diseases</li> </ul>	
Less components <ul> <li>Lower revision procedures rate</li> </ul>	
Lower cost	
It is possible implant artificial sphincter in the future	












	6	Ģ	
	S 2 2 B Q Q 1 E 0 B = E 11 1 0 0 # B = _	DM	Cursores de pressi
AUD CCM: 350 ml	100	500 400 X	PV = 43 PA = 43 PD = 0 Ti 0+42
PPE: 70 cmH20	I manual a march and a march al	200	PD = 5 To 17db Aberbure(2)
	- 100 2 8 D/a 6 7	1	PD = 12 Tr 19(3)
	\$ " mummelun - mumelun - harring		PD = 10 Ti 1913 Pbcco.mkumo(5) PV = 55 PA = 44
			PD = 12 Tr 19:6 Exc0x(0) PT = 20 PA = 01
	100		PD=0 Ti 19:0 Cechamardo(7) PV=56 PA=62
			Ti 20.0 Cursor de fluxo
			Dar spåo de Flaxo 34,7; Tempo sté máxim 20 ; Flaxo máxim Plaxo médio 8 mil/ Volarne 293 st

	<i>v</i>	PHILA	018 Delphia
AUD	6 5 4 8 9 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	DM	Cursores de pressi
		-430	PV =         PA =           PD =         Ti           C COM(2)         PV =           PD =         Ti           C Absrburg(2)         PV =           PV =         PA =           PD =         Ti
CM: 350 ml E: 64 cm H20			C Data micro(5) PV PA PD Ta C Data micro(5) PV PA PD C Percip(5)
			PY =         PA = 64           PD = -113         Ti 105           FD =         PA =           PD =         PA =           PD =         PA =           PD =         PA =           PD =         PA =           PT =         PA =           PT =         PA =           PT =         PA =           PD =         PA =           PD =         PA =           PD =         PA =           Cursor do fluxo         Fino
	Lucion 10 10 10 10 10 10 10 10 10 10 10 10 10	000 600 400 200	Duração do Fluxo Tempo até máximo Fluxo máximo 

# Control C









# Mr. R. O. (DOB July 27, 1941)

1998: Radical P for T3 CaP with adjuvant radiation and 2 years of ADT Mild to moderate SUI (1-2

pads/day) 2001: Transurethral injection of Macroplastique® x3 (as part of clinical trial)



OPHILADELPHIA


# Mr. R. O. (DOB July 27, 1941)


SUI worsened; Macroplastique eroded through injection site and removed transurethrally

Developed vesico-urethral anastomotic stenosis that settled with dilation and daily self cath.

Video-urodynamics

- Supine filling capacity 200 cc and SUI with coughing seen.
- Upright filling capacity 190 cc and DO up to 75 cm water







Mr. R. O. (DOB July 27, 1941)	PHILADELPHIA
Feb 2005: sphincter revision with addition of second • Improved to 1-2 pads/day, still taking anticholinergic	I cuff
2009: increased leakage to 2-3 pads/day	

Change drug or increase anticholinergic	
Add in AdVance sling or alternative	
More injectable agent	
Revise sphincter	
Urinary diversion	

# Mr. R. O. (DOB July 27, 1941)

Feb 2009: Revision – 4 cm distal cuff replaced outside bulbospongiosus muscle Sphincter activated 1 month later UI markedly better, now on 10 mg solifenacin Jan 2010 incontinence worsened Cystoscopy – both cuffs looked functional Video-urodynamics • Capacity: 200 cc with DO up to 70 cm water, contraction settled and VLPP 138 cm water

Op	tions for management	O PHILADELPHIA
1. 2. 3. 4. 5.	Change drug or increase anticholinergic Add in AdVance sling or alternative More injectable agent Revise sphincter Urinary diversion	

# Mr. R. O. (DOB July 27, 1941)

Sep 2010: Cystoscopy and 100u Botulinum toxin A injected Oct 2010: 1 pad/day Mar 2011: stable response but developed colorectal cancer and in Jul 2011 underwent APR Sep 2011: repeat Botox (100u) Repeat Botox q 6 mo. with good response



# O PHILADELPHIA

#### 57 years

Radical prostatectomy

Gleason 4.4

Urinary incontinence

Underwent reposition sling

# OPHILADELPHIA

#### Good results

But PSA relapse after one year

Underwent radiation therapy

Urinary incontinence

What is the proposal?	PHILADELPHIA
Do nothing	
Another sling – compressive	
Artificial sphincter	
Double cuff	
Transcorporeal cuff	





# PHILADELPHIA

65 year old

Radical retropubic prostatectomy

**Diabetes – controlled** 


Artificial sphincter

18 months after surgery





CS 2018	CS 2018
PHILADELPHIA	PHILADELPHIA
Case 5	72 year old patient Radical prostatectomy in 2015 Urinary incontinence and impotence since the surgery Physiotherapy without improvement AUS implanted




# What would do you suggest?


Change the cuff to smaller size Add one more cuff Transcorporal cuff Possible infection  $\rightarrow$  antibioticotherapy Erosion  $\rightarrow$  removal of the system


	PHILADELPHIA
Endoscopy without erosion	
No infection	
What are your recommendation?	
















#### rostate Cancer


#### Pharmacologic Treatment in Postprostatectomy Stress Urinary Incontinence


Maria Teresa Filocamo <sup>a,\*</sup>, Vincenzo Li Marzi <sup>a,\*</sup>, Giulio Del Popolo <sup>b</sup>, Filippo Cecconi <sup>a</sup>, Donata Villari <sup>a</sup>, Michele Marzocco <sup>a</sup>, Giulio Nicita <sup>a</sup>


EUROPEAN UROLOGY 51 (2007) 1559-1564




















DO DRUG TREATMENT			
ANTIMUSCARINICS			
DRUG	DOSE	FREQUENCY	
Tolterodine	1 – 2 mg	TID <sup>1</sup>	
Tolderodine XL	2 - 4 mg	Once-daily	
Oxybutynin <sup>*</sup>	2,5 - 5 mg	BID <sup>2</sup> or TID	
Oxybutynin XL	5 - 15 mg	Once-daily	
Oxybutinyn transdermal patch	3.9 mg/d	1 patch BIW	
Oxybutinyn gel 10%	1 ml	Once-daily	
Trospium*	20 mg	BID or TID	
Trospium XL	60 mg	Once-daily or BID	
Propiverine	15 mg	BID or TID	
Propiverine XL	30 mg		
Solifenacin**	5 – 10 mg	Once-daily	
Fesoterodine**	4 – 8 mg	Once-daily	
Darifenacin**	7.5 – 15 mg	Once-daily	
B3 Agonist			
Mirabregon	50 mg	Once-daily	

